Hello Dose Semaglutide Review

Hello Dose has the most explicitly described screening process of any operator in this comparison and the highest prices. Our research (September 1, 2026) found a clinically serious practice whose commercial proposition is difficult to justify against the rest of the market.

The Clinical Process Is Described Properly

Most sites in this category say a provider "reviews your intake." Hello Dose says what that actually consists of:

"Hello Dose programs are prescribed and monitored by licensed Nurse Practitioners operating within their scope of practice. Every patient completes a comprehensive medical intake, contraindication screening, and virtual consultation prior to receiving treatment. Ongoing follow-ups ensure safe dose titration and side-effect monitoring."

Three things there are unusual. Naming contraindication screening as a discrete step matters for a drug class carrying a boxed warning for medullary thyroid carcinoma and MEN 2. Requiring a virtual consultation before treatment puts the clinical decision ahead of dispensing. And committing to follow-ups for titration and side-effect monitoring describes continuing care rather than a subscription that ships vials. The acknowledgement that NPs work within scope of practice is a further mark of a practice that takes its regulatory position seriously.

A Named, Accountable Founding Clinician

"Founded and Clinically Led by Bracha Banayan, FNP — Board-Certified Family Nurse Practitioner and founder of Hello Dose and IV Drips. Bracha specializes in longevity-focused care and GLP-1–supported weight management and has trained and personally selected each Hello Dose Nurse Practitioner to ensure consistent, high-quality patient care."

A named clinician who founded the practice, holds board certification and personally selects the clinical staff is a genuine accountability structure, and considerably more than the anonymous provider networks most competitors use.

The Compounding Disclaimer Is Correct

"Unlike FDA-approved drugs, compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. They are prepared by licensed compounding pharmacies under pharmacist supervision and state pharmacy board oversight. Medication eligibility and prescriptions are determined solely by licensed medical providers based on clinical appropriateness."

Accurate, and it correctly identifies state pharmacy board oversight as the applicable regime rather than implying federal approval. The post-shortage caveat still applies: with the tirzepatide shortage resolved in October 2024 and semaglutide in early 2025, lawful 503A compounding depends on a documented clinical reason for the individual patient.

Now the Prices

Semaglutide: $495 per month. Tirzepatide: $695 per month. Those are three to five times what comparable compounded providers charge. Cora Health publishes compounded semaglutide from $99 and tirzepatide from $135. Gentle Health charges $135–$199 and $169–$269 by dose band. PepScribe starts at $99 and $209. More pointedly, $495 and $695 per month are above what manufacturer-direct programmes charge for the actual FDA-approved products. A patient paying $695 a month for compounded tirzepatide could buy brand-name Zepbound through LillyDirect for less — an approved medicine, reviewed by the FDA, at a lower price. Hello Dose's clinical process is better than most. It is not several hundred dollars a month better than every other option, and it does not close the gap against an approved product costing less.

The Microdosing Tiers Invert the Logic

Semaglutide Microdosing: $395/month. Tirzepatide Microdosing: $595/month. Microdosing GLP-1s is not an approved protocol and is not supported by the registrational trial evidence that established these drugs' efficacy and safety. Here it is offered as the cheaper tier — $100 less than the standard programme — which positions a less-evidenced protocol as the budget option. A patient economising will be steered toward the choice with the weaker clinical basis, and at $395 they would still be paying roughly three times Cora's or Gentle Health's full-dose price.

What Is Not Published

No compounding pharmacy is named and no 503A/503B status given. No BMI or clinical eligibility threshold, despite the emphasis on screening. No lab requirement stated. No specific follow-up cadence behind the "ongoing follow-ups" commitment. No dose-tier structure — it is unclear whether $495 covers a maintenance dose or only a starting one. No founding year for the practice, no state coverage list, and no refund or cancellation terms. A "$100 off your first month" offer is promoted.